S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM (2013/4/9)|
|Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments (2013/3/12)|
|Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer (2013/2/19)|
|Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer (2013/2/13)|
|Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013 (2013/3/5)|
|Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting (2013/4/1)|
|Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production Conference (2013/2/26)|
|Peregrine Announces Participation at Upcoming Investor Conferences (2013/2/26)|
|U.S. Food and Drug Administration Approved 30% More Drugs in 2012 (2013/2/14)|
Click above to view more mutual fund data and stats for pphm - Peregrine Pharmaceuticals, Inc..